(8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl acetylsulfamate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl acetylsulfamate
• 英文别名: [(8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] N-acetylsulfamate
• 化学式: C₂₀H₂₅NO₅S
• 分子量: 391.488
• InChiKey: CJNDUJZSQWUJEN-XSYGEPLQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  27
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  97.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl acetylsulfamate 在 oestrone sulphatase 作用下， 生成 雌酚酮
  参考文献：
  名称：

  Oestrone 3-O-(N-acetyl)sulphamate, a potential molecular probe of the active site of oestrone sulphatase

  摘要：

  N,N-Dialkylated derivatives of the steroid sulphatase inhibitor, oestrone 3-O-sulphamate (EMATE) are weak reversible inhibitors of the enzyme. N-Acetylated-EMATE (8), but not the benzoyl derivative, inhibits the enzyme irreversibly, albeit less potently than EMATE and will allow hitherto difficult radiolabelling on the sulphamate group to facilitate investigation of the enzyme inactivation mechanism. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(97)10167-6
• 作为产物：
  描述：

  雌酚酮 在 sodium hydride 、 三乙胺 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 反应 20.0h， 生成 (8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl acetylsulfamate
  参考文献：
  名称：

  由氟代硫酸盐和酰胺合成N-酰基氨基磺酸盐

  摘要：

  开发了针对N-酰基氨基磺酸盐的新型合成策略 。有趣的是，氟代硫酸盐是一种新兴的亲电试剂，用于构建氨基磺酸盐核。这排除了氯磺酰基异氰酸酯和氨磺酰氯的处理。与酰胺组合，合成了多种多样的N-酰基氨基磺酸盐，包括功能化的生物活性化合物。此外，初步结果表明该方法也适用于获得N-硫代酰基氨基磺酸酯。

  DOI：

  10.1021/acs.joc.8b02785

文献信息

• [EN] ESTRATRIENE DERIVATIVES<br/>[FR] DERIVES D'ESTRATRIENE
  申请人：CRYPTOPHARMA PTY LTD

  公开号：WO2004101595A1

  公开（公告）日：2004-11-25

  Compounds and methods for modulating mesenchymal cell function, for instance smooth muscle and fibroblast proliferation or cytokine expression, and for treating conditions associated with mesenchymal cell function, for instance airway hyperresponsiveness associated with asthma. The compounds also supress inflammation. The compounds are a class of estratriene derivates, and includes various derivatives of 2-methoxyestradiol comprising a group A, including a substituted aromatic substituent in the 2-, 6- or 17- position.

  调节间叶细胞功能的化合物和方法，例如平滑肌和成纤维细胞增殖或细胞因子表达，以及治疗与间叶细胞功能相关的疾病，例如与哮喘相关的气道高反应性。这些化合物还抑制炎症。这些化合物是一类雌三烯衍生物，包括各种2-甲氧基雌二醇衍生物，其中包括A组，包括在2-、6-或17-位置有取代芳香基团。
• Estratriene Derivatives
  申请人：Stewart George Alastair

  公开号：US20070275935A1

  公开（公告）日：2007-11-29

  Compounds and methods for modulating mesenchymal cell function, for instance smooth muscle and fibroblast proliferation or cytokine expression, and for treating conditions associated with mesenchymal cell function, for instance airway hyperresponsiveness associated with asthma. The compounds also suppress inflammation. The compounds are a class of estratriene derivates, and includes various derivatives of 2-methoxyestradiol comprising a group A, including a substituted aromatic substituent in the 2-, 6- or 17-position.

  化合物和方法用于调节间充质细胞功能，例如平滑肌和成纤维细胞增殖或细胞因子表达，并用于治疗与间充质细胞功能相关的疾病，例如与哮喘相关的气道过度反应。这些化合物还可抑制炎症。这些化合物是一类雌三烯衍生物，包括2-甲氧基雌二醇的各种衍生物，其中包括A组，包括2-，6-或17-位取代芳香基取代物。
• ENT-STEROIDS AS SELECTIVELY ACTIVE ESTROGENS
  申请人：Schering Aktiengesellschaft

  公开号：EP1169336A1

  公开（公告）日：2002-01-09
• ESTRATRIENE DERIVATIVES
  申请人：Cryptopharma Pty Ltd

  公开号：EP1625143A1

  公开（公告）日：2006-02-15
• [EN] ENT-STEROIDS AS SELECTIVELY ACTIVE ESTROGENS<br/>[FR] ENT-STEROIDES UTILISES COMME OESTROGENES SELECTIVEMENT ACTIFS
  申请人：SCHERING AG

  公开号：WO2000063228A1

  公开（公告）日：2000-10-26

  This invention describes the new ent-steroids of general formula (I) in which R?1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R19¿ have the meanings that are indicated in the description, as pharmaceutical active ingredients that in vitro have a higher affinity to estrogen receptor preparations of rat prostates than to estrogen receptor preparations from rat uteri and in vivo preferably a preferential action on bone rather than the uterus and/or pronounced action with respect to stimulation of the expression of 5HT2a-receptors and transporters, their production, their therapeutic use and pharmaceutical forms for dispensing, which contain the new compounds. The invention also describes the use of steroids, on which the (8α-H, 9β-H, 10α-H, 13α-H, 14β-H)-gonane skeleton is based, for treatment of estrogen-deficiency-induced diseases and conditions.